Scodeller earned his degree in Biomedical Engineering from the University of Mendoza, Argentina and his PhD in Chemistry from the University of Buenos Aires in 2011. Following a two-year postdoctoral fellowship in materials science in CNEA (Argentina), he joined the laboratory of Dr. Erkki Ruoslahti (recipient of the 2022 Lasker Award) in La Jolla, USA, in 2013 to complete a two-year postdoctoral fellowship in the field of the tumor microenvironment.
In 2015, he moved to the University of Tartu, Estonia, to conduct postdoctoral research in the laboratory of Dr. Tambet Teesalu, a pioneer in the field of tumor-penetrating peptides.
In 2017, he was awarded a Starting Grant from the Estonian Research Council, and in 2018 was promoted to Associate Professor at the University of Tartu. In 2021 he was awarded a Ramón y Cajal contract and in 2025 he obtained tenure as a CSIC researcher.
His research focuses on identification of new targeting peptides and therapeutic targets in disease, precision drug delivery to solid tumors (breast cancer, glioma, neuroendocrine carcinomas), and new immunotherapies based on tumor macrophage reprogramming.
Using in vivo peptide phage display, Scodeller has co-identified targeting peptides for cancer, brain injuries, and Alzheimer´s disease, which have been used by over 40 independent research groups for targeted drug delivery and have led to 5 patents, 4 of which are licensed to companies. He has obtained 7 research grants (totaling ca. 1M€) as a principal investigator and supervised 3 doctoral thesis and 5 masters thesis.